Posted by admin on Jan 31, 2025 in |
Introduction: Being an Oleaceae family member, Nyctanthes arbor-tristis, known as Night jasmine or Harashingar, is a legendary plant with enormous therapeutic potential. Research on the different plant parts, such as the leaf, flower, fruit, seed, and bark revealed the phytochemicals that were responsible for the primary pharmacological activities. These phytochemicals included glucose, oleanic acid, glycosides, carotene, tannic acid, flavanoids, benzoic acid, and essential oils. The present article discusses the taxonomy, vernacular names, distribution, botanical description, habitat, cultivation and propagation, traditional uses, phytoconstituents, and pharmacological activities of the plant. The article also describes the study carried out on the characterization of microscopy of the stem transverse section. Objective of the Study: To investigate the microscopic characterization of the stem of Nyctanthes arbor-tristis. Method: The thin transverse section of the plant stem was treated with several chemicals like alcohol (10%, 30%, 50%, 90%, 100%) and with xylene (10%, 30%, 50%, 90%, 100%). The dyes, saffranine, and methylene blue were used to stain the stem sections. DPX assisted in making a permanent...
Read More
Posted by admin on Jan 31, 2025 in |
Background: Drug-induced gingival overgrowth (DIGO) is a common side effect of certain medications used for non-dental purposes, notably anticonvulsants, calcium channel blockers (CCBs), and immunosuppressants. These drugs, despite differing pharmacologically, inhibit intracellular calcium ion influx, leading to a decrease in collagenolytic activity and an increase in fibroblasts and collagen synthesis, ultimately causing gingival overgrowth. Case Presentation: A 54-year-old male presented with significant gingival enlargement and periodontal disease. Clinical examination revealed generalized mild to moderate calculus, erythematous and indurated gingiva with severe periodontal attachment loss, and tooth mobility. Despite scaling and root planning, the gingival enlargement persisted, necessitating surgical intervention. Open flap debridement was performed, leading to a successful outcome with no recurrence of gingival enlargement after one year of follow-up. Discussion: The case highlights amlodipine-induced gingival overgrowth, a recognized side effect of CCBs. The exact mechanisms remain unclear, with both inflammatory and non-inflammatory pathways implicated. The inflammatory process involves cytokine upregulation, leading to fibroblast proliferation and fibrotic gingival hyperplasia. The case underscores the importance of early diagnosis, medication management,...
Read More
Posted by admin on Jan 31, 2025 in |
Background: There are numerous anti-seizure drugs on the market, but side effects at the highest dosage that can be tolerated account for the majority of prescription discontinuations. Research on Musa paradisiaca’s synergistic activity is of utmost importance in getting insight into its anti-seizure potential. Methods: Anti-seizure activity of Musa paradisiaca on generalized tonic-clonic seizure was evaluated using standard maximal electroshock seizure method and on absence seizure using pentylenetetrazole test. Both models had 6 groups each: vehicle control, active control, high dose herb, low dose herb, combination of active control (sub-therapeutic dose) with low dose herb & combination of active control (sub-therapeutic dose) with high dose herb. Results: In MES model Musa paradisiaca in high dose prevented both tonic extension and tonic flexion. In PTZ model Musa paradisiaca in high dose and low dose significantly increase the latency of onset of seizures and decrease the duration of seizure compared to vehicle control. There was no significant effect on onset of 1st myoclonic jerk. Addition of Musa paradisiaca to the sub-therapeutic...
Read More
Posted by admin on Jan 31, 2025 in |
Metabolic syndrome is continuously on the rise, due to a changed lifestyle and long ageing. The abnormal function of mTOR/AMPK, a cellular energy switch, is the main cause behind this pathogenesis, which is now defined as “metabolic syndrome”. Here, we have screened the metabolites of shilajit, obtained from the HRAMS analysis, to select the direct activators of AMPK, by using computational exploration, through molecular docking and ADMET prediction. The shilajit has been in clinical use in Ayurvedic medicine, for centuries, to enhance the overall vitality, immunocompetence and aphrodisiac potential, but scientific data are lacking to support its therapeutic claims. The shilajit, of Upakarma Ayurveda was purchased from the market and analyzed through HRAMS, which reported the presence of 5467 metabolites. Their CID numbers were obtained from the PubChem portaland docked against the AMPK (AMPK active site PDB ID-4CFF), by using LibDock and Discovery Studio to do a structure-based screening, ADME (absorption, distribution, metabolism, excretion) and toxicity prediction. Among them, Reproterol (CID-25654) and Ambruticin (CID-6918547) showed the best binding energy,...
Read More
Posted by admin on Jan 31, 2025 in |
Aim: This study aimed to evaluate the efficacy and safety profile of DPP-4 inhibitors as add-on therapy in patients with type 2 diabetes. The study is important because DPP-4 inhibitors have been widely prescribed, and understanding their comprehensive effects is essential for better patient outcomes. Methods: An extensive literature search has been conducted using multiple databases, such as PubMed, Cochrane Library, Scopus, Web of Science, and Google Scholar. All results have been analyzed based on inclusion and exclusion criteria, and their findings are displayed statistically to ensure accurate comparisons between treatment groups. Results: DPP-4 inhibitors demonstrate significant efficacy in managing type 2 diabetes mellitus (T2DM), leading to a reduction in glycated hemoglobin (HbA1c) levels by 0.9% (9 mmol/mol; p < 0.0001) and fasting blood glucose (FBG) by 1.15 mmol/L (19.82 mg/dL; p = 0.001) among a cohort of 105 individuals. Notably, sitagliptin exhibited a remarkable HbA1c reduction of 1.66% (19 mmol/mol; p < 0.0001). These inhibitors also significantly curtailed glycemic variability, as evidenced by a mean amplitude of glycemic...
Read More
